{
    "nct_id": "NCT04025879",
    "official_title": "A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer",
    "inclusion_criteria": "* Participants with suspected or histologically confirmed Stage IIA (> 4 cm) to IIIB (T3N2) non-small cell lung carcinoma (NSCLC) with disease that is considered resectable\n* No brain metastasis\n* Treatment-naive for NSCLC (no prior systemic anti-cancer treatment)\n* Ability to provide surgical or biopsy tumor tissue for biomarkers\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤ 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with an active, known or suspected autoimmune disease\n* Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV)\n* Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy for NSCLC\n* Prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}